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‘Stat rosa pristina nomine. Nomina nuda tenemus’
(The ancient rose remains by its name, names only are
left to us)
From ‘The name of the rose’ by Umberto Eco
Introduction
The quest for accurate terminologies and classifications is a con-
stant source of dilemmas in medicine and science and a particu-
larly topical and controversial subject in the field of cardiovascular
diseases.
The Cardiology community is torn between the concept of
personalized medicine and ambiguous diagnostic categories, often
describing non-entities. The debate on what are the best classifi-
cations is ignited by the exponential increase in knowledge which
parallels with a constant rising in complexity. The intent to capture
the intrinsic either physiological or pathological features of each
individual may clash with the need to categorize as no classifi-
cation can represent the complexity of reality beyond a certain
extent.
In this viewpoint we will discuss how terminology and classifica-
tions evolved in the field of cardiovascular diseases and what are the
main nomenclature deadlocks. We will start from the philosophical
basis of this enduring debate to eventually approach practical dilem-
mas, using the example of cardiomyopathies and heart failure (HF).
Terminology and classifications.
A long philosophical journey
Terminology invokes the language labels attached to a concept, a
constant source of dilemmas throughout the history of philosophy,
















































.. science and, of course, medicine. The debate on terminology
and classifications date at least to the fifth century BC.1 Plato
dedicates a significant proportion of his dialogues to the so-called
‘theory of forms’ or ‘theory of ideas’ attempting to answer the
major question ‘what is the essence of things?’. He supposed
that the object was essentially the form and that the phenomena
(ϕα𝜄νω: to appear) were shadows mimicking the form [the dis-
crepancy between essence and phenomena is described vividly in
the allegory of the cave (Republic)].1
Aristotle interpreted reality in a more empirical way. He intro-
duced the notion that abstract concepts represent descriptions of
things that have been classified by describing their attributes. He
introduces the idea of categories which refer to qualities. This posi-
tion rejects the Platonic extreme realism and establishes the view
of a universal as being that of the quality within a thing and every
other thing individual to it. A substantial form is the essence of a
substance and since only universals are definable, substantial forms
are universals.2
During the Middle-Age several philosophers and theologians
(William of Ockam, Roscellinus and others) rejected realistic
theories and embraced nominalism. While Plato’s (and Platonist)
view was that different objects are the way they are, in virtue of the
existence of a universal, according to nominalism, only particulars
exist and they stem from our representational system or from our
language (the way we speak of the world). Human conventions
tend to group objects or ideas into categories, which exist because
we decide to name them and not because there is a universal
abstraction.3
More recently Immanuel Kant postulated that universals are not
real, but are ideas in the mind of rational beings, fundamental
categories of pure reason intrinsically linked to the rationality of
the subject making the judgment.4 The 20th century philosopher
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2 Viewpoint
Ludwig Wittgenstein focused his work mainly on the relationship
between language and reality, acknowledging the great limitations of
terminology which is highly dependent on the context and assumes
a private meaning which is understood differently by individuals
involved in a conversation.5
It is on the ground of this long and enduring controversy that
modern taxonomy was first developed in the 16th and 17th cen-
tury, a long way before the 20th century era of clinical descriptions,
such as Standardized Nomenclature of Diseases (SND) and Inter-
national Classification of Diseases (ICD).
The case of cardiomyopathies
Several definitions and classifications have been proposed
in the attempt of capturing the multifaceted nature of
cardiomyopathies.6,7 Specifically, the European Society of Car-
diology (ESC) proposes a classification that supports an empiric
approach based on phenotypic expression.7
The development of these classifications represents laudable
efforts that surely provide some clarity in the field. Classifications
utilize categories and names that should cover the variable expres-
sion of a cardiac condition encapsulating the true essence of a
specific disease. Several examples may be used to describe the
intrinsic failure of this assumption. The name ‘hypertrophic car-
diomyopathy’ (HCM) suggests a pathological process characterized







































.. where features highly suggestive of HCM are present, such as for
example lateral deep T-wave inversion, or family history of HCM,
but the wall thickness is measured 11 or 12 mm at the left ventricu-
lar apex (not exceeding the threshold of 15 mm as per international
guidelines8). If we interpret guidelines and the value of the name
rigorously, we would probably hesitate to call the aforementioned
condition HCM (Figure 1). Post-mortem interpretation of cardiac
findings in decedents of sudden death with (or without hypertro-
phy) offers similar challenges9,10: some suggest that HCM may be
diagnosed without hypertrophy, but with significant myocardial dis-
array (a profound derangement of normal myocyte alignment at
histology); conversely unexplained hypertrophy in the setting of
sudden death may not be considered in the same disease spectrum
of HCM.11
The same can be said of other cardiomyopathies. The name
‘arrhythmogenic right ventricular cardiomyopathy’ evokes a con-
dition characterized by arrhythmias and where the right ventricle
is the affected chamber.12 Longitudinal studies have shown that
although a significant proportion of patients experience arrhyth-
mias, many patients have a very stable course.13 Moreover, blaming
only the right ventricle appears inappropriate as the left ventricle
has recently been shown to be affected too (or may be the only
chamber affected).
The intrinsic risks of a phenotypic classification (or nomen-
clature) are to stop the diagnostic quest at the first appearance
and to erroneously consider a morphologic trait as a specific
disease.
Figure 1 The relationship between essence, phenotype and name. Hypertrophic cardiomyopathy is used as an example to explain how these
three aspects are inherently related, with several dilemmas affecting the link between them. The ‘non-equal’ symbol represents the missing link
between the three aspects.
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Viewpoint 3
The case of heart failure
A certain degree of nomenclature complexity in HF is almost
unavoidable as we are referring to a syndrome and not a disease.
The ESC guidelines differentiate between three subgroups, bas-
ing this classification on left ventricular ejection fraction: HF with
reduced ejection fraction (HFrEF), HF with mid-range ejection frac-
tion (HFmrEF) and HF with preserved ejection fraction (HFpEF).14
This classification provides clarity, but at the same time suffers from
some limitations. The ejection fraction is a feature that does not
discriminate aetiologies and a patient with reduced left ventricular
ejection fraction may suffer from ischaemic heart disease or from
an inherited dilated cardiomyopathy.15
Even more causal heterogeneity may be found in the group
classified as HFpEF that may be truly considered a ‘nosographic
trap’. Many randomized clinical trials have shown important results
in patients with HFrEF.14 The same cannot be said for patients with
HFpEF.16 Although the reasons for this disparity are still unclear, a
main driver for the unsuccess of clinical trials in HFpEF may be
the nosographic chaos characterizing this matter. Indeed, HFpEF
is not a description of a clinical entity, but the illustration of a
‘non-entity’. The definition ‘HFpEF’ risks to be superficial mixing
a wide range of different clinical entities, each requiring specific
treatment. The failure of clinical trials assessing the potential
of various drugs in HFpEF may be caused by this terminology
deadlock.
The issue of differential diagnosis
In the field of HF and cardiomyopathies, differential diagnosis is
inevitably arduous, because different disease entities may exhibit
the same phenotype and a specific disease may present differ-
ent phenotypes. An increasing number of studies attempt to test
and compare certain features to demonstrate a practical utility
in differentiating A from B. However, this experimental approach






















































.. of reality and therefore relies on the assumption that A and B
are separate entities. However, nature usually does not follow
dichotomous rules. An example is provided by the issue of dif-
ferential diagnosis between physiological adaptation to exercise
and cardiomyopathies. We should concede that an athlete may
have a cardiomyopathy or that a patient with a cardiomyopa-
thy may be an athlete and the phenotype is a combination of a
physiological and a pathological process (Figure 2). Using another
example, the assumption that A and B (for example dilated car-
diomyopathy and arrhythmogenic right ventricular cardiomyopa-
thy) are two separate clinical entities is a postulate: A and B are dif-
ferent because we arbitrarily and conventionally decide to call them




The explosion of ‘big data’, and the constant developments in sci-
ence and novel technologies, is impacting (and will impact even
more in the next future) not only on our understanding of cardio-
vascular diseases, but also on classifications and nomenclature.17
The dissection of reality to an individual level with the purpose
of providing a personalized care will certainly come at a price:
our ability to cluster and categorize will become remarkably
challenging when the quest for the particular will be taken to the
extreme and the infinitesimal, losing the awareness of the universal
(Figure 3).
Perhaps this process will be accompanied by a move of the focus
from clusters and categories to effects and practical repercussions
on clinical management. In other words, nomenclature and cate-
gories may become tools which are too infinitesimally detailed and
complicated to be handled from a human perspective. This would
result in a convergence on only few pragmatic algorithms aimed at
Figure 2 Dichotomous approach to differential diagnosis between athlete’s heart and dilated cardiomyopathy (DCM) (A). The combination
of DCM and physiological adaptation to exercise is possible and therefore an approach based on the recognition of ‘shades of grey’ rather
than a mutually exclusive interpretation of clinical findings would account for the limitations of our knowledge based on empiric reality (the
phenotype) (B). ECG, electrocardiogram; FH, family history; LBBB, left bundle branch block; LV, left ventricle; LVEF, left ventricular ejection
fraction; LVH, left ventricular hypertrophy; MRI, magnetic resonance imaging; RV, right ventricle; RVH, right ventricular hypertrophy; SCD,
sudden cardiac death; TWI, T-wave inversion; VO2, oxygen consumption.
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4 Viewpoint
Figure 3 Personalized medicine and raising complexity in definitions and nomenclature. The process of bridging the gap between universal and
singular is likely to result in enormous confusion, clashing with the human intellectual capacity to rationalize reality into meaningful categories.
The phenotypic variability may be infinitesimally high if one considers the individual patient, rather than categories (increased variability is
represented by the increase in geometrical complexity – yellow geometric figures).
Figure 4 Heart failure may be categorized in a myriad of different disease entities (small dots). Simplification into few major clinical outcomes
and focus on practical management may solve the problem of overcomplexity, shifting the target away from categories. Artificial intelligence
may enable the clinician to control overcomplexity through a useful interpretation of multiple names and terminologies attached to disease.
Nomenclature and complex classifications would gain meaning and relevance if artificial intelligence provides tools to decipher categories as
single entities with practical effects which are specific to each single category. CMR, cardiac magnetic resonance.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Viewpoint 5
Table 1 Key messages
1. The field of cardiovascular medicine is becoming increasingly complex, due to our ability to dissect reality to an individual level with the purpose
of providing a personalized care.
2. The issue of terminology and classifications is crucial in medicine and extend to other realms of knowledge. From Plato’s ‘theory of ideas’, to
Aristotle’s ‘categories’, to the Middle-Age debate on universals and the controversy between nominalism and realism to Wittgenstein’s ‘private
meaning’ and incommunicability, nomenclature has been a constant source of dilemmas throughout the history of philosophy and science.
3. Current classifications, especially in heart failure and cardiomyopathies, are mainly based on the phenotype.
4. The possibility to dissect reality to the extreme (for example through advanced imaging and genetics) may overcome a phenotype-focused
approach. However, this is an operation that comes at a price with an impact on our ability to cluster and categorize, an exercise that would
become remarkably challenging.
5. The issue of intelligibility of an increasing complex reality made by too many categories may be partly resolved by artificial intelligence which
may be crucial in simplifying complexity and in creating a framework that may be easily understandable and clinically actionable by the physician.
practical management and at the improvement of major clinical out-
comes. Artificial intelligence, which is increasingly penetrating the
world of medicine, may offer a different scenario, where computa-
tional analysis would allow to rapidly simplify categories multiplied
to a great detail and feedback to the clinician in an intelligible form18
(Figure 4).
Conclusions
The debate on nomenclature and terminology is lively in medicine
and particularly in the field of HF and cardiomyopathies. Current
classifications of cardiovascular diseases are mainly based on the
phenotype.
The constant evolution of personalized medicine represents a
shift from a ‘one size fits all approach’ to the tailoring of inter-
ventions for prevention and treatment of disease to the individ-
ual characteristics of each patient. This paradigm shift will cer-
tainly be accompanied by epistemological, ontological and termi-
nological challenges. The eternal problem of universals and of the
singular–universal relation, which is a constant theme in philoso-
phy and science, will be magnified to the extreme. Although current
phenotypic classifications may be perceived as superficial, empirical
and indeed too universal, the ability to dissect reality to the indi-
vidual will possibly lead to an enormous complexity in definitions
and nomenclature, with thousands of different pathological types
described. The appropriate balance between extreme complexity
and over-simplification will need to be found, possibly introducing
artificial intelligence in the process of interpretation of the increas-
ing amount of available information (Table 1).
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